New hope for lymphoma patients: experimental drug TORL-5-700 enters human trials
NCT ID NCT07439653
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called TORL-5-700, given alone or with other medicines, for people with B-cell Non-Hodgkin lymphoma that has come back or stopped responding to treatment. The goal is to find a safe dose and see if it can shrink tumors. About 155 adults will take part in this early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTOLOGICALLY CONFIRMED RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
Stanford University
RECRUITINGStanford, California, 94305, United States
-
UCLA
RECRUITINGSanta Monica, California, 90404, United States